(Q57418400)

4

0 references

Carlos Cruchaga

object named as

Carlos Cruchaga

1

0 references

author name string

Elena Ansó

2

0 references

Ana Rouzaut

Journal of Biological Chemistry

3

0 references

language of work or name

English

0 references

publication date

6 July 2006

0 references

published in

0 references

volume

281

0 references

issue

38

0 references

page(s)

27744-27752

0 references

cites work

Inhibition of HIV-1 reverse transcription: basic principles of drug action and resistance

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Nucleoside and nucleotide inhibitors of HIV-1 replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Non-nucleoside inhibitors of HIV-1 reverse transcriptase inhibit phosphorolysis and resensitize the 3'-azido-3'-deoxythymidine (AZT)-resistant polymerase to AZT-5'-triphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Inhibition of phosphorolysis catalyzed by HIV-1 reverse transcriptase is responsible for the synergy found in combinations of 3'-azido-3'-deoxythymidine with nonnucleoside inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Antiviral effects of phosphonoformate (PFA, foscarnet sodium).

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Mechanism by which phosphonoformic acid resistance mutations restore 3'-azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

In Vivo Additive Antiretroviral Effect of Combined Zidovudine and Foscarnet Therapy for Human Immunodeficiency Virus Infection (ACTG Protocol 053)

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Relationship between 3′-Azido-3′-Deoxythymidine Resistance and Primer Unblocking Activity in Foscarnet-Resistant Mutants of Human Immunodeficiency Virus Type 1 Reverse Transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Analysis of the combined effect of two linear inhibitors on a single enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Synergistic inhibition of HIV-1 reverse transcriptase by combinations of chain-terminating nucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Pyrophosphate analogues as inhibitors of herpes simplex virus type 1 DNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Mechanism of phosphonoacetate inhibition of herpesvirus-induced DNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Kinetic evidence for interaction of human immunodeficiency virus type 1 reverse transcriptase with the 3'-OH of the incoming dTTP substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200

Hypophosphoric acid is a unique substrate of pyrophosphorolysis catalyzed by HIV-1 reverse transcriptase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M603360200